Evaluation of CD38 expression in Sudanese patients with chronic lymphocytic leukemia

被引：3

作者：

Abdelgader E.A. ^{[1
]}

Eltayeb N.H. ^{[2
]}

Eltahir T.A. ^{[3
]}

Altayeb O.A. ^{[4
]}

Fadul E.A. ^{[4
]}

Abdel Rahman E.M. ^{[3
]}

Merghani T.H. ^{[5
]}

机构：

[1] Department of Pathology, Faculty of Medicine, Al Neelain University, Khartoum

[2] Department of Physiology, Faculty of Medicine, Al Neelain University, Khartoum

[3] Khartoum Radioisotope Center, Khartoum

[4] Flow Cytometry Laboratory for Leukemia and Lymphoma Diagnosis, Khartoum

[5] Department of Physiology, Faculty of Medicine, University of Khartoum, Khartoum

来源：

BMC Research Notes | / 11卷 / 1期

关键词：

CD38; CLL; Flowcytometer; Leukemia;

D O I：

10.1186/s13104-018-3926-0

中图分类号：

学科分类号：

摘要：

Objective: The objective of this study was to evaluate the cluster of differentiation-38 (CD38) expression in Sudanese patients with chronic lymphocytic leukemia (CLL) and to determine its association with clinical and laboratory characteristics of the disease. Results: We conducted a cross-sectional study on 99 patients diagnosed with CLL in Khartoum Oncology Hospital in Khartoum, Sudan. Immunophenotyping and CD38 expression levels were measured with four-color flowcytometry. The results of physical examination and blood analyses were used for assigning a modified Rai clinical staging system. The collected data were analyzed using the Statistical Package for the Social Science, version 22 (SPSS Inc., Chicago, IL, USA). According to our findings, the frequencies of 7%, 20%, and 30% cutoff levels of CD38 expressions were 68.7%, 41.4%, and 36.4% respectively. CD38 cutoff level of 7% showed a significant association with hemoglobin concentration (P = 0.04), whereas other cutoff levels showed insignificant results. All the three cutoff levels showed insignificant associations with the other clinical and laboratory variables. In conclusion, the CD38 expression at a cutoff level of 7% seems to be more valuable clinically than higher cutoff levels in Sudanese CLL patients. © 2018 The Author(s).

引用

共 36 条

[1]

Bockstaele F., Verhasselt B., Philippe J., Prognostic markers in chronic lymphocytic leukemia: A comprehensive review, Blood Rev, 23, pp. 25-47, (2009)

[2]

Matutes E., Attygalle A., Wotherspoon A., Diagnostic issues in chronic lymphocytic leukemia (CLL), Best Pract Res Clin Hematol, 23, pp. 3-20, (2010)

[3]

Matutes E., Owusu-Ankomah K., Morilla R., Garcia Marco J., Houlihan A., Que T.H., Catovsky D., The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL, Leukemia, 8, 10, pp. 1640-1645, (1994)

[4]

Mehta K., Shahid U., Malavasi F., Human CD38, a cell-surface protein with multiple functions, FASEB J., 10, 12, pp. 1408-1417, (1996)

[5]

Deaglio S., Vaisitti T., Zucchetto A., Et al., CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells, Semin Cancer Biol, 20, 6, pp. 416-423, (2010)

[6]

Chevallier P., Penther D., Avet-Loiseau H., Et al., CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukemia, Br J Haematol, 116, 1, pp. 142-150, (2002)

[7]

Deaglio S., Aydin S., Grand M.M., Et al., CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells, Mol Med, 16, 3-4, pp. 87-91, (2010)

[8]

Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., Et al., Ig v gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia, Blood, 94, 6, pp. 1840-1847, (1999)

[9]

Del Poeta G., Maurillo L., Venditti A., Et al., Clinical significance of CD38 expression in chronic lymphocytic leukemia, Blood, 98, 9, pp. 2633-2639, (2001)

[10]

Ibrahim S., Keating M., Do K.A., Et al., CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia, Blood, 98, 1, pp. 181-186, (2001)

← 1 2 3 4 →